| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Farah Khaznadar, Kristina Bojanić, Omar Khaznadar, Ana Jurić, Marija Hefer, Kristina Kralik, Ana Petrović, Ana Hrženjak, Ana Lončar, Justinija Steiner, Martina Smolić and Robert Smolić |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| European Union-Next Generation EU through programme funding of the University of Osijek (UNIOS)-Institutional Project |
581-UNIOS-46 |
|
| Corresponding Author |
Martina Smolić, Full Professor, Research Dean, Department of Translational Medicine, Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, Crkvena 21, Osijek 31000, Croatia. msmolic@fdmz.hr |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Type 2 diabetes mellitus; Sodium-glucose cotransporter 2 inhibitors; Two-dimensional shear wave elastography; Ultrasound-guided attenuation parameter; Sterol regulatory element-binding protein 1c; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Microsomal triglyceride transfer protein |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease lacks effective pharmacologic therapies and robust biomarkers for monitoring treatment response. In this prospective observational study, sodium-glucose cotransporter 2 inhibitors therapy was associated with modulation of selected circulating lipogenesis biomarkers and a modest reduction in liver stiffness of uncertain clinical relevance, whereas steatosis measures remained largely unchanged over 6 months. |
| Publish Date |
2026-10-21 02:09 |
| Citation |
Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i10/125505.htm |
| DOI |
https://doi.org/10.4254/wjh.125505 |
